NasdaqGS:TSLA
NasdaqGS:TSLAAuto

Latest News In Electric Vehicles - Aptera Motors Advances Toward Scalable Solar Vehicle Production

Aptera Motors Corp., a solar mobility company focused on ultra-efficient transportation, has commenced construction of its validation vehicle assembly line at its Southern California facility. This development marks a shift from prototype builds to a systematic assembly process, with engineers and technicians refining the systems to aid Aptera’s progression toward scalable manufacturing. The assembly line setup, which includes precision assembly fixtures for consistent production, is crucial...
NYSE:SPOT
NYSE:SPOTEntertainment

Spotify (NYSE:SPOT): Evaluating Valuation After Strong Q3 Results and Upbeat Guidance

Spotify Technology (NYSE:SPOT) just announced its third quarter earnings, delivering higher revenue and profitability compared to last year. The company also shared new guidance for the next quarter, which gives investors plenty to consider. See our latest analysis for Spotify Technology. Spotify’s impressive third quarter results have powered a strong rally, with the latest buyback and ambitious revenue guidance adding fuel to upbeat investor sentiment. While there has been some short-term...
NYSE:EPAM
NYSE:EPAMIT

EPAM Systems (EPAM) Is Up 13.7% After Strong Q3, Raised Guidance and $1B Buyback Announcement

EPAM Systems reported third quarter 2025 results with revenues of US$1,394.37 million and net income of US$106.82 million, while also raising its full-year revenue growth and earnings guidance and announcing a new US$1 billion share repurchase program. The introduction of new AI offerings and the expansion of share buybacks highlight EPAM's focus on AI-driven services and confidence in its ongoing business momentum. We'll explore how EPAM's higher revenue guidance and investment in AI-native...
NasdaqGS:IFRX
NasdaqGS:IFRXBiotechs

InflaRx (IFRX): Assessing Valuation After Positive Phase 2a Results for INF904 in HS and CSU

InflaRx (NasdaqGS:IFRX) released positive topline results from its Phase 2a basket study evaluating INF904 in hidradenitis suppurativa and chronic spontaneous urticaria. The company reported rapid and consistent clinical improvements as well as a favorable safety profile, fueling investor interest. See our latest analysis for InflaRx. Investors have taken notice of InflaRx’s momentum recently, especially after the promising Phase 2a results. The company’s 1-week share price return of 33% and...